Finally, to investigate whether our targeted combination strategy could be transferred to CRC cell lines with endogenous KRAS mutations, we co-treated HCT-116 and LoVo cells with DbαEGFR-scTRAIL and SM83 in 3D cultures. This evidence concerns the gene KRAS and colorectal carcinoma.